Journal article
Management of dyslipidaemia in patients with comorbidities-facing the challenge
European heart journal. Cardiovascular pharmacotherapy, v 11(2), pp 164-173
13 Mar 2025
PMID: 39719399
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
This review aims to examine the evidence on the benefits and risks of lipid-lowering drugs in patients with liver disease. Elevated liver enzyme levels often lead to cautious discontinuation of these drugs, potentially withholding from patients their benefit in reducing cardiovascular disease morbidity and mortality. Using a literature search of PubMed, we examine the efficacy and safety profiles of various lipid-lowering agents, including statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, fibrates, and icosapent ethyl, focusing particularly on their potential side effects related to liver health. A major challenge in the assessment of drug-induced hepatotoxicity is the fact that it relies heavily on case reports rather than real-world evidence. There is currently a lack of robust evidence on lipid-lowering therapy in people with pre-existing liver disease. Nevertheless, we have attempted to summarize the available data for all the drugs mentioned in order to provide guidance for the treatment of patients with liver dysfunction. This review highlights the need for further research to optimize treatment strategies for patients with coexisting liver and cardiovascular disease.
Metrics
1 Record Views
Details
- Title
- Management of dyslipidaemia in patients with comorbidities-facing the challenge
- Creators
- Lisa Frühwald - Wilhelminen HospitalPeter Fasching - Wilhelminen HospitalDobromir Dobrev - Baylor College of MedicineJuan Carlos Kaski - St George's, University of LondonClaudio Borghi - IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'OrsolaSven Wassmann - Cardiology Pasing, Faculty of Medicine, Munich and University of the Saarland, 66123 Homburg/Saar, GermanyKurt Huber - Sigmund Freud Privatuniversität WienAnne Grete Semb - Diakonhjemmet HospitalStefan Agewall - Karolinska InstitutetHeinz Drexel - Vorarlberg Institute for Vascular Investigation and Treatment
- Publication Details
- European heart journal. Cardiovascular pharmacotherapy, v 11(2), pp 164-173
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:001418219800001
- Scopus ID
- 2-s2.0-105001221018
- Other Identifier
- 991022197399104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Cardiac & Cardiovascular Systems
- Pharmacology & Pharmacy